Active substanceMethyl ethylpyridinolMethyl ethylpyridinol Similar drugsTo uncover Cardiocipine solution d / infusion BIOSINTEZ, PAO Russia Cardiocipine solution w / m in / in BIOSINTEZ, PAO Russia Methyl ethylpyridinol solution for injections ATOLL, LLC Russia Methyl ethylpyridinol solution for injections ELLARA, LTD. Russia Methyl ethylpyridinol solution for injections Company DEKO, LLC Russia Methyl ethylpyridinol-Eskom solution for injections ESKOM NPK, OAO Russia Emoticon Optics drops d / eye SYNTHESIS, JSC Joint-stock Kurgan Society of Medical Preparations and Products Russia Emoxibel solution d / infusion Emoxibel solution for injections BELMEDPREPARATY, RUP Republic of Belarus Emoxibel drops d / eye BELMEDPREPARATY, RUP Republic of Belarus Emoxibel solution w / m in / in BELMEDPREPARATY, RUP Republic of Belarus Emoxipine® drops d / eye MOSCOW ENDOCRINE FACTORY, FSUE Russia Emoxipine solution w / m in / in MOSCOW ENDOCRINE FACTORY, FSUE Russia Emoxipine drops d / eye FARMENT FIRM, LLC Russia Emoxipine solution for injections MOSCOW ENDOCRINE FACTORY, FSUE Russia Emoxipine-AKOS drops d / eye SYNTHESIS, JSC Joint-stock Kurgan Society of Medical Preparations and Products Russia Emoxipine-Acti solution d / infusion Aktifarm, OOO Russia Dosage form: & nbspSolution for intravenous and intramuscular injection. Composition:1 ml of the solution contains:Active substance: methyl ethylpyridinol hydrochloride 30 mg;Excipients: solution of sodium hydroxide 1 M to pH 4.8 - 5.8; water for injection up to 1 ml. Description:Transparent colorless or slightly colored liquid. Pharmacotherapeutic group:Antioxidant. ATX: & nbspS.01.X.A Other drugs for the treatment of eye diseases Pharmacodynamics:Angioprotector, reduces the permeability of the vascular wall, is an inhibitor of free radical processes, an antihypoxant and an antioxidant.Reduces blood viscosity and platelet aggregation, increases the content of cyclic nucleotides (cyclic adenosine monophosphate and cyclic guano Zinmono-phosphate) in platelets and brain tissue, has fibrinolytic activity, reduces the risk of developing hemorrhages, contributes to their resorption. Expands coronary vessels, in the acute period of myocardial infarction limits the magnitude of the focus of necrosis, improves the contractility of the heart and the function of its conductive system.At high arterial pressure has an antihypertensive effect.In acute ischemic impairment of cerebral circulation reduces the severity of neurologic symptoms, increases tissue resistance to hypoxia and ischemia. Pharmacokinetics:The volume of distribution is 5.2 liters. Metabolised in the liver. The half-life is 18 min. Clearance - 214.8 ml / min. It is excreted by the kidneys. Indications:In neurology and neurosurgery in complex therapy: hemorrhagic stroke in the recovery period, ischemic stroke, transient cerebral circulatory disorders, chronic cerebral circulatory insufficiency, craniocerebral trauma (CCT); postoperative period in patients with craniocerebral trauma, operated on for epi-, subdural and intracerebral hematomas, combined with a brain contusion.In cardiology in complex therapy: acute myocardial infarction; prevention of reperfusion syndrome; unstable angina. Contraindications:- Increased individual sensitivity to the drug Emoxipin®;- Pregnancy, lactation;- Children under 18 years. Dosing and Administration:In neurology and neurosurgery, the preparation Emoksipin® is administered intravenously at a rate of 20-30 drops per minute at a daily dose of 10 mg / kg for 10-12 days. Subsequently, they switch to intramuscular injection of 60-300 mg 2 -3 times a day for 20 days. Before the administration, the preparation Emoksipin® is diluted in 200 ml of sodium chloride solution isotonic.In cardiology, drip intravenously at a rate of 20-40 drops per minute at a dose of 600-900 mg of a solution of Emoxipin in 200 ml of sodium chloride solution isotonic 1 to 3 times a day for 5-15 days, depending on the course of the disease, followed by transition to intramuscular injection of 60-300 mg 2-3 times a day for 10-30 days. Side effects:Excitation, drowsiness, increased blood pressure, reaction at the injection site (pain, itching, burning), headache, pain in the heart, allergic reactions, dyspepsia, blood clotting disorder. Overdose:Data on overdose are absent. Interaction:Pharmaceutically incompatible with other medicines. Special instructions:Treatment should be carried out under the control of blood pressure and blood coagulability. Form release / dosage:Solution for intravenous and intramuscular injection 30 mg / ml. Packaging:For 1 or 5 ml in neutral glass ampoules grade HC-1 or NS-3 or imported.5 ampoules per contour cell packaging made of polyvinylchloride film and foil of aluminum printed lacquered or flexible packaging on the basis of aluminum foil, or without foil.For 1 or 2 contour mesh packages (with foil or without foil), along with instruction on the use of the preparation, a knife or scapegrator ampullum is placed in a pack of cardboard.For 20, 50 or 100 contiguous cell packs with foil (for inpatient), together with 10, 25 or 50 instructions for the use of the drug, respectively, with knives or scarifier ampoules placed in a box of cardboard or in a box of corrugated cardboard.When packing ampoules with rings or break points, knives or scarifier ampoules do not. Storage conditions:List B. In the dark place at a temperature of no higher than 25 ° C.Keep out of the reach of children. Shelf life:2 years. The drug should not be used after the expiration date. Terms of leave from pharmacies:On prescription Registration number:LSR-008767/09 Date of registration:02.11.2009 Expiration Date:Unlimited The owner of the registration certificate:MOSCOW ENDOCRINE FACTORY, FSUE MOSCOW ENDOCRINE FACTORY, FSUE Russia Manufacturer: & nbspMOSCOW ENDOCRINE FACTORY, FSUE Russia Information update date: & nbsp2016-08-27 Illustrated instructions × Illustrated instructions Instructions